Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

All TrialsPhase N/A

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zejula (niraparib) / GSK, J&J

NCT03025867: Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Approved for marketing

N/A

Niraparib

Tesaro, Inc.

Recurrent Ovarian Cancer

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites